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Cystic craniopharyngiomas are considered the most common intracranial non-
glial tumor in children with the tendency for cyst formations. The aim of this 
study was to evaluate the effect of intracystic phosphorus 32 (P32) therapies on 
controlling the growth of the cystic component of craniopharyngioma.
Materials & Methods
This clinical study was conducted on 47 patients with cystic craniopharyngioma 
from March 1998 to June 2012 at Shohada Tajrish Hospital, Tehran, Iran. 
Patients were treated with stereotactic intracystic P32. The mean cyst volume 
was 23.5 ml, and the dose of radiation to the inner cyst wall was 250 Gy.
results 
The overall response rate was 78.1% and the mean survival was 113.1±11months. 
The survival rate at 1, 3, 5, and 10 years after p32 therapy was 91%, 77%, 
73%, and 52%, respectively. There was no mortality related to the procedure and 
no visual or endocrinal deterioration. Visual improvement occurred in 88% of 
patients presented with recent deterioration due to the cyst enlargement. 
Conclusion
Intracystic p32 therapy was an effective and almost safe procedure for the 
treatment of cystic component of craniopharyngioma. 
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introduction 
tumor originating from the embryonic epithelial cells of the craniopharyngeal 
duct, or from the metaplasia of the squamous epithelial cell. It is considered the 
most common intracranial non-glial tumor in children (1). Craniopharyngioma is 
composed of 1.2%–4% of the primary intracranial neoplasms and accounts for 5%–
10% of intracranial tumors in children (2, 3). 
Although pathologically it has a benign appearance corresponding to WHO grade ӏ, 
the clinical behavior is aggressive causing morbidity by damaging the hypothalamus, 
pituitary gland, and optic chiasm (4, 5). Craniopharyngioma has variable appearances 
and presentations; therefore, treatment of each case should be individualized (2). 
Surgical resection via microsurgery or endoscopic approaches is particularly for 
tumors with large solid part. There are high mortality and morbidity in open surgery 
(6). Even after total resection, recurrence rate after 10 years is around 18% (6, 7). 
Cysts of the craniopharyngioma usually adhere to the critical surrounding neural 
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and vascular structures and are frequently considered 
inoperable (8). Accordingly, less aggressive surgery 
along with adjuvant therapy such as external radiation 
and intracystic therapy can comparatively provide the 
control of tumor with less morbidity than aggressive 
surgery (4, 8).
Intracystic therapy using substances including β 
emitting radioisotopes (phosphousr32 (P32), yttrium90, 
aurum198, and rhenium186) destroys the epithelial lining 
of the cyst wall and suppresses the re-accumulation of 
the cyst (5, 9, 10). Intracystic treatment provides durable 
cyst shrinkage and volume reduction by simply repeated 
aspiration (3, 5). Nonetheless, it is not effective on the 
solid part of the tumor.                                                                                                  
The aim of this study was to determine the treatment 
results for patients with cystic craniopharyngioma after 
intracystic instillation of P32 radioisotope.
Material & Methods 
This clinical study was conducted on 47 patients 
with cystic craniopharyngioma from March 1998 to 
June 2012 at Shohada Tajrish Hospital, Tehran, Iran. 
Previously, in the same treatment center, P32 therapy 
was used on 22 patients with shorter duration of follow-
up from 1998 to 2005 (1). The current study focused 
on the outcome of 47 patients with longer follow-up 
period from 1998 to 2012. Six patients were excluded 
from this study due to their unwillingness. Data were 
collected from the patients’ medical records regarding 
presenting symptom, neurological and ophthalmological 
examinations, previous therapies, endocrinological tests, 
imaging, and definite pathology. 
The most common presenting symptoms were headache 
and poor vision. Other presenting symptoms included 
ocular deviation, hemiparesis, cognitive changes 
decline, and hearing problems. Fourteen patients 
(34.1%) presented with progressive cyst enlargement 
during the routine follow-up without any significant 
symptoms. Endocrinopathy was detected in 87.7% and 
five patients had normal endocrinal profiles. Patients 
had undergone treatments before P32, which included 
craniotomy (39 patients), external beam radiation (36 
patients), ventriculoperitoneal (VP) shunt (17 patients), 
gamma knife therapy (7 patients), stereotactic biopsy 
(one patient), and transsphenoid surgery (TSS) (one 
patient). 
The indication of P32 therapy was a documented cyst 
enlargement after unsuccessful prior therapies and 
when the diagnosis was first made by a stereotactic 
biopsy of a suprasellar cystic mass. The patients were 
divided into three groups according to brain CT scan or 
MRI before P32 intracystic therapy: 1) solitary cystic, 
2) multicystic: with more than one cyst and small solid 
part, and 3) mixed solid and cystic. For delivery of P32 
the stereotactic system, Riecherd-mundinger was used if 
the omayo reservoir had not been implanted before or if 
it was not functional. The head was fixed in Riecherd-
mundinger under a local anesthesia and intravenous 
sedation without intubation. Frontal burr hole was 
placed and the cyst punctured by a cannula with its sharp 
tip. After aspiration of the large cysts and reassurance 
of the target, ommaya or similar shunt was placed into 
the cyst. Contrast material was injected via the reservoir 
of ommaya and X-Ray taken to exclude any leakage 
from the cyst. The cyst volume was measured using the 
vepro image processor. The amount of P32 that deliver 
250 GY to the cyst wall for about five-half-life (around 
70 d) was calculated. With safety routine precautions 
in handling the radioactive substance, the determined 
dose of P32 was delivered via the catheter. Then, all the 
radioactive contaminated materials were handled with 
routine care and disposed of. A neurosurgeon evaluated 
the patients neurologically and after 48 hours monitored 
them by a radioactive detector. Ideally, there should be 
no systemic exposure to radioactivity so that the only 
radioactive detected in the cyst and in the ommaya, but 
not in the liver. The patients were discharged from the 
hospital and followed up every week for a month, then 
every three months for one year, and after that each year. 
All patients were examined with CT scan, endocrinal lab 
data, and ophthalmological examination. 
The treatment response was defined according to the 
changes, which occurred in the cyst size in the CT scan 
examination in four statuses as follows: 
1) Complete response, when the cyst disappeared 
2) Partial response, when the cyst size decreased, but 
was not disappeared 
3) Stable, when no changes were seen in the cyst size 
4) Progressive, when the cyst size was enlarged 
Statistical analysis was performed using SPSS 17 
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therapy with P32, and after that there were no changes in 
the endocrine profiles. All the patients were monitored by 
radioactive tracer around the head and liver for detection 
of any leakage from the cyst within the first 48 hours. 
Accordingly, no patient showed radioactive detection in 
the liver that means there was no radioisotope leakage 
from the tumor cyst. 
Complications related to the therapy were few and 
included one temporally CSF leakage from the scalp 
wound, one brain abscess, one superficial wound 
infection, and one temporal sixth cranial nerve palsy. 
There was no post-operative mortality.
discussion 
There is no uniform protocol for the treatment of the 
craniopharyngioma. However, therapy should minimize 
the risk of complications and should be individualized for 
any patient (2). Surgery (transcranial and endoscopic) is 
often the first choice treatment (6, 7, 11). Radical resection, 
if feasible, offers the best chance for disease control and 
possibility of cure (12). However, it is a challenge, with 
possible complications including visual and vascular 
injuries, endocrinal hypothalamic damage, obesity, and 
behavioral changes (13-15). Repeated surgery has a high 
failure rate (16), and the outcome of surgery depends on 
the expertise of the surgeon (5). Gross tumor removal has 
been reported around 45%-85% with a 5-year recurrence 
free survival around 76%-86.9%, and after partial tumor 
removal a 5-yr recurrence-free survival about 40%-
41.7% (6, 11). After partial resection with radiotherapy 
there were 5 yr recurrence-free survival rate about 90% 
and 10 yr overall survival rate more than 90% (3, 4, 
15). The cysts of craniopharyngioma are difficult to 
remove completely because of the attachments to the 
surrounding vital structures (8); therefore, repeated 
aspirations are needed (3, 5). Intracystic therapies 
include instillation of radioactive substances (bleomycin 
and interferon) which destroys the secretary epithelial 
lining of the cyst. These therapies lead to shrinkage of 
the cyst, providing a good local control and reducing 
the need for repeated aspiration and further surgeries 
(3, 5). Intracystic β emitting radioisotopes include 
P32, aurum198, rhenium186, and yttrium90 (5, 8, 9). 
Although there is no overall difference clinically among 
isotopes, some authors are in favor of P32 because of 
(Chicago, IL, USA) and survival rate was evaluated 
by Kaplan-Meier curve to describe the duration of the 
survival from the time of the injection of P32 to the end 
of the study or the patient’s death.
results
Forty-one patients (61% men) with an age range of 4 
to 54 yr (mean age of 17.2±11.3 yr) were enrolled. The 
mean cyst volume was 23.5 ml (range from 4.5 ml to 
80 ml). Nine patients (22%) showed complete response 
to P32 therapy and cyst disappeared. In addition, 23 
patients (56.1%) showed partial response and cyst 
decreased in size, so overall response rate including 
complete response and partial response was 78.1%. 
Seven (17%) patients showed no change in the cyst size 
while two (4.8%) patients showed an increase in the cyst 
size. Overall, 17 patients (41.46%) required no further 
treatment after one session of P 32 therapy and among 
them six showed complete response, and 11 showed 
partial response. In the responsive group, six patients 
had drainage and 12 needed to receive further courses 
of therapy (10 patients had two,  one patient had three, 
and one patient had four courses of treatment). The mean 
follow-up duration of patients was 58.02 months (7-158 
months). The 1, 3, 5, and 10-year survival was 91%, 
77%, 73%, and 52%, respectively. Using Kaplan-Meier 
survival analysis, mean survival was 113.1 ±11months 
(95% CI, 91.5 -134.6) (Figure 1). Out of patients with 
craniopharyngioma, seven died due to tumor progression, 
three due to causes other than enlargement of the cyst 
and one due to enlargement of other cysts in the tumor 
did not receive P32 therapy, in spite of observing the 
good treatment response in the cyst that received P32 
therapy.                                                                                                                                                                                                                              
Prior to the treatment, 39 patients (95.1%) had impaired 
vision. After P32 therapy, 18 patients (43.9%) showed 
improvement in their vision, 21 (51.2%) had unchanged 
vision, and two (4.9%) who had normal vision prior 
to therapy remained normal. Therefore, there was no 
new visual impairment after the therapy. Among the 
39 patients with decreased vision, 22 patients (53.6%) 
had a recent visual deterioration because of the cyst 
enlargement whereas, after P32 therapy, 18 of them 
(81.8%) showed visual improvement.
Overall, 36 patients had endocrinopathy before the 
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craniopharyngioma (adamantinomatous and squamous 
papillary types), comparing the effect of P32 in 
cystic craniopharyngiomas according to their specific 
pathology may have prognostic value.
in  Conclusion, cystic craniopharyngioma treatment 
with intracystic p32 was a safe therapy for the cystic 
component of craniopharyngioma. It might be a good 
choice for a long duration of time in purely cystic 
craniopharyngioma and could eliminate or reduce the 
need for surgery or repeated aspiration. However, P32 
therapy cannot prevent the growth of the solid part or 
appearance of new cysts.
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a mean β energy release of 0.69MeV, longer half-life 
(14.3 d), and less tissue penetration (2–8 mm). The latter 
item reduces the risk of damage to the adjacent structures 
including visual pathway (1, 5). P32 is a highly effective 
and safe treatment and may be the first and only therapy 
required in solitary cystic craniopharyngioma for a long 
time (17, 18).
In our study, intracystic P32 instillation led to tumor 
response rate of 78.1%, comparable to previous 
studies with response rate of 67%-88% (5, 10, 17-19). 
Moreover, 5 and 10-yr survival in our research was 73% 
and 52%, respectively; this   is consistent with some 
studies (20, 21) and slightly lower than the other studies 
(22). Generally, these differences in the survival rate can 
be attributed to the fact that there are multiple variables 
affecting the survival in the patients. It is not uniform in 
all of the studies. 
The visual improvement has routinely been reported in 
most patients in different studies (19, 21, 23-25). In our 
study, visual improvement was 43.9%, which is also 
comparable with prior studies (19, 21, 24, 25). There 
was no visual decline after the procedure, but several 
studies showed visual deterioration after the therapy 
(21, 25, 26). The possible causes of visual deterioration 
(26) were the increase in the size of the solid part, new 
cyst formation, and failure of the cyst collapse. The 
presence of optic atrophy before the brachytherapy had 
a remarkable association with the visual deterioration. In 
the present study, the major determinant of improvement 
of the visual function was a recent deterioration of vision 
due to the cyst enlargement. It included 22 out of all 39 
patients with visual defects. After therapy with P32, 
vision improved overall in 18 patients (43.9%); that is, 
81.8% of the patients with recent deterioration showed 
amelioration of visual function. 
Regarding systemic leakage of P32 from the cyst, 
gamma scan 48 h after the therapy showed no cyst 
leakage, but some studies reported 10% leakage after 
instillation of P32 (20). 
It will be helpful to investigate the change in the efficacy 
of intracystic P32 therapy after a period of serial 
drainage of the cyst, aiming to reduce the total volume 
of the cyst before P32 therapy. It also contributes to the 
reduction of the total dose of P32, so reducing the risk 
of its side effect. Considering different pathologies of 
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